Novo Nordisk A/S
Market Cap
$170.74B
P/E Ratio
10.79
EPS
$3.56
Dividend Yield
4.70%
52-Week Range
$35.85 — $82.57
Volume
6.88M
Avg Volume
24.48M
Beta
0.27
P/E (TTM)
10.79
Forward P/E
1.80
PEG Ratio
-8.66
P/S (TTM)
3.56
P/B (TTM)
5.68
P/FCF
-133.70
EV/EBITDA
43.17x
EV/Sales
—
ROE (TTM)
0.61%
ROA (TTM)
0.19%
ROIC
0.10%
Gross Margin
0.81%
Operating Margin
0.41%
Net Margin
0.34%
Debt/Equity
0.67
Current Ratio
0.80
EPS Growth (YoY)
-0.05%
Revenue Growth (YoY)
-0.07%
EPS Growth (3Y)
+0.25%
EPS Growth (5Y)
+0.22%
Sales Growth (3Y)
+0.20%
Sales Growth (5Y)
+0.19%
EPS Est (This Year)
$21.31
EPS Est (Next Year)
$21.62
Dividend Yield
—
Annual Dividend
$0.41
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
2025-08-18
Cash/Share
$6.07
Buy
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $47.00(22.3% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
4.44B
Float
3.19B
Free Float %
71.74%
RSI (14)
32.56
SMA 20
$56.72
SMA 50
$53.26
SMA 200
$57.08
ATR (14)
3.00
Volatility (Week)
0.09%
Volatility (Month)
0.05%
Pattern
—
1 Day
-0.51%
1 Week
-2.35%
1 Month
-16.48%
3 Months
+7.53%
6 Months
-1.50%
1 Year
—
YTD
-6.24%
All-Time High
$93.80
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
DK
Exchange
NYSE
IPO Date
1981-04-30
Employees
77406
CEO
Maziar Mike Doustdar
Index Membership
—
Website
https://www.novonordisk.com
Novo Nordisk A/S (NVO) is a healthcare company in the drug manufacturers - general industry listed on the NYSE. With a market capitalization of $170.74B, a P/E ratio of 10.79, and a dividend yield of 4.70%, NVO is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare NVO against other stocks using dozens of fundamental and technical filters.
Novo Nordisk A/S (NVO) has a trailing twelve-month (TTM) P/E ratio of 10.79. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Novo Nordisk A/S (NVO) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Novo Nordisk A/S (NVO) has a market capitalization of $170.74 billion, classifying it as a large-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Buy" rating on Novo Nordisk A/S (NVO) with an average score of 2.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $47.00 implies 22.3% upside from the current price.
Novo Nordisk A/S (NVO) has returned -6.24% year-to-date. Past performance does not guarantee future results, but these figures reflect the stock's recent price trajectory relative to the broader market.